Skip to content
value.today

Antares Therapeutics, Inc.

🇺🇸 Boston, Massachusetts, USABiotechnologyFounded 2025
Total raised
$70 M
2 rounds on record
Latest round
$30 M
May 2025
First round on record
Mar 2025
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Antares Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2025$30 MNo. 2$10 to $50 million

Antares Therapeutics, Inc.: Raise no. 2, May 2025

Investors in this round

35 investors had bought by the notice of May 15, 2025: 35 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Antares Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$30 M of $137 M offered; $107 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Adam Friedman · Executive Officer, Director
  • Andrew Fedder · Executive Officer
  • Brian Piper · Executive Officer
  • Jean-Francois Formela · Director
  • Jeffrey Albers · Director
  • Keith Flaherty · Director
  • Menelas N. Pangalos · Director
  • Shelley Chu · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Andrew Fedder, General Counsel. Newest notice filed May 15, 2025. Read the notice at the SEC.

equitySEC
Mar 2025$40 MNo. 1$10 to $50 million

Antares Therapeutics, Inc.: Raise no. 1, Mar 2025

Investors in this round

3 investors had bought by the notice of Mar 12, 2025: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Antares Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$40 M of $40 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Adam Friedman · Executive Officer, Director
  • Andrew Fedder · Executive Officer, Director
  • Brian Piper · Executive Officer, Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Andrew Fedder, General Counsel. Newest notice filed Mar 12, 2025. Read the notice at the SEC.

debt, optionsSEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Antares Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (May 2025).

    SEC Form D · May 2025

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · May 2025

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

4 named in official filings. Open an investor to see everything it has backed.

Investors in Antares Therapeutics, Inc.
InvestorKindAmountRoundRoleSource
Select Biotechnology PortfolioFund or asset manager$0 Mheldnot statedHolds shares (fund report, May 2026)SEC Form N-PORT
Fidelity Growth Company FundFund or asset manager$0 Mheldnot statedHolds shares (fund report, May 2026)SEC Form N-PORT
Fidelity Growth Company K6 FundFund or asset manager$0 Mheldnot statedHolds shares (fund report, May 2026)SEC Form N-PORT
Fidelity Series Growth Company FundFund or asset manager$0 Mheldnot statedHolds shares (fund report, May 2026)SEC Form N-PORT

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Antares Therapeutics, Inc.
NameRoleNamed in
Adam FriedmanExecutive officerMay 2025
Andrew FedderExecutive officerMay 2025
Brian PiperExecutive officerMay 2025
Adam FriedmanDirectorMay 2025
Jean-Francois FormelaDirectorMay 2025
Jeffrey AlbersDirectorMay 2025
Keith FlahertyDirectorMay 2025
Menelas N. PangalosDirectorMay 2025
Shelley ChuDirectorMay 2025
Andrew FedderDirectorMar 2025
Brian PiperDirectorMar 2025